报告题目:Nanoparticles for Drug Targeting: Past, Present and Future
报 告 人: Prof. Gert Storm
1Dept. Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands ;2 Dept. Biomaterials Science & Technology (BST), MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands
报告摘要: One most active sector of research within the field of nanomedicine has been the design of nanoparticulate pharmaceuticals for targeted drug delivery. In fact, novel and established nanoparticle systems continue to flourish in the research laboratory. However, the number of such systems that have been approved for the treatment of patients is still limited. Examples are Caelyx/Doxil (doxorubicin), Myocet (doxorubicin), DaunoXome (daunorubicin), Marqibo (vincristine), Onyvide (irinotecan), Onco-TCS (vincristine), Vyxeos (cytarabine and daunorubicin), Abraxane (paclitaxel) and Onpattro (transthyretin-directed siRNA). While these examples illustrate that significant advances have been made over the years in making nanoparticulate nanomedicines a clinical reality, there is nevertheless growing sceptism in the scientific literature regarding the future and clinical applicability of such targeted nanopharmaceuticals. In this presentation, I will discuss the arguments raised to justify this negative attitude as well as my different view on the current status and future of the use of nanoparticles for drug targeting.
报告人简介：Gert Storm, professor (Targeted Drug Delivery) at the Department of Pharmaceutics (80% employment), obtained his Ph.D. degree in 1987 at the Utrecht University. In 1988-1989, he was a visiting scientist at Liposome Technology Inc. in Menlo Park, USA, and visiting assistant professor at the School of Pharmacy, UCSF, San Francisco. In 1990-1991, he became senior research scientist at Pharma Bio-Research Consultancy B.V. in Zuidlaren, The Netherlands. During this period he contributed to the design, co-ordination and evaluation of clinical pharmacological studies. In September 1991 he took up his position at the Utrecht University. He is honorary professor (Biomacromolecular Drug Delivery) at the University of Copenhagen. From 2012 on, he is also professor (Targeted Therapeutics) at the MIRA institute of the University of Twente (20% employment). Furthermore, he keeps a position (seconded) at the University Medical Center Utrecht (UMCU) (Division Imaging).
To date, he has co-authored more than 540 publications (h-index >90). The design, characterization and (pre)clinical testing of targeted nanomedicine formulations is the core activity. Additionally, the implementation of imaging-guided drug delivery protocols (using e.g. SPECT, MRI, PET) is a major research objective.
From 2014 on, he is every year included in the lists of The World’s Most Influential Scientific Minds of Thomson Reuters (Highly Cited Researchers) and more recently Clarivate Analytics.
Over the last decade, clinical translation of academic results has become a vital element of Prof. Storm’s ambition, as exemplified by the clinical development of liposomal corticosteroids (by the creation of the spin-off company Enceladus Pharmaceuticals BV in 2005), the clinical breast cancer study at the UMCU evaluating image-guided targeted doxorubicin delivery with hyperthermia (follow-up of the HIFU-CHEM project), his involvement in public-private partnership projects, i.e. EC (coordinator Meditrans (FP6), partnering in 4 FP7 projects and 2 Horizon2020 projects), CTMM (PI HIFU-CHEM), NanoNextNL (director Program Drug Delivery), TI-Pharma and AgentschapNL. Over the years, he also obtained significant funding for applied research from STW and several large industries (e.g. Astellas, Astra Zeneca, Novartis). He is on the Board of the CLINAM (European Foundation for Clinical Nanomedicine) organization in Basel, and the PRC (Phospholipid Research Center) in Heidelberg.